Niels Peter Mo Slashedller

This inventor holds 4 USPTO granted patents. Top assignee: Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V. . Active years: 1998-2000.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Niels Peter Mo Slashedller. Retrieved from https://idiyas.com/inventor/niels-peter-mo-slashedller

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 4

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 3

Forward Citations = 27(Granted Patents)

Location History:

Munchen, DE (1999)
Copenhagen, DK (1998 - 2000)

Company Filing History:

4 out of 1,336

Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V.

patents

Years Active: 1998-2000

Loading Chart...

4 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6030822 - Extracellular signal-regulated kinase, sequences, and methods of (2000-02-29),

2. 5955592 - Nucleic acid encoding novel protein phosphotyrosine phosphatase PTP-D1 (1999-09-21),

3. 5856111 - Methods for identifying modulators of insulin receptor phosphorylation (1999-01-05),

4. 5831009 - Protein phosphotyrosine phosphatases PTP-D1 (1998-11-03),

Title: Niels Peter Mo Slashedller: Innovator in Protein Phosphatase Research

Introduction

Niels Peter Mo Slashedller is a prominent inventor based in Copenhagen, Denmark. He has made significant contributions to the field of biochemistry, particularly in the study of protein phosphatases. With a total of 4 patents to his name, Slashedller's work has advanced our understanding of various biological processes.

Latest Patents

Among his latest patents is the invention related to extracellular signal-regulated kinase, ERK-5. This invention encompasses nucleic acid molecules coding for ERK-5, polypeptides, and methods for detecting ERK-5 in samples. It also includes therapeutic methods for treating conditions such as diabetes mellitus and Alzheimer's disease using ERK-5 agonists or antagonists. Another notable patent involves the novel protein phosphotyrosine phosphatase PTP-D1, which includes isolated PTP-D1 protein and methods for its production and identification.

Career Highlights

Niels Peter Mo Slashedller is affiliated with the Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V., where he conducts his research. His work has been instrumental in the development of new therapeutic strategies targeting protein phosphatases.

Collaborations

Throughout his career, Slashedller has collaborated with esteemed colleagues such as Axel Ullrich and Karin Bach Mo Slashedller. These collaborations have further enriched his research and contributed to the advancement of the field.

Conclusion

Niels Peter Mo Slashedller's innovative work in protein phosphatase research has led to significant advancements in biochemistry. His patents reflect a commitment to improving therapeutic approaches for various diseases.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]